{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "central A\u03b2 clearance", "discoidal high-density lipoprotein", "intranasal administration", "peripheral compensatory A\u03b2 metabolism"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38085773", "DateCompleted": {"Year": "2023", "Month": "12", "Day": "16"}, "DateRevised": {"Year": "2024", "Month": "06", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "12", "Day": "12"}], "Language": ["eng"], "ELocationID": ["e2304213120", "10.1073/pnas.2304213120"], "Journal": {"ISSN": "1091-6490", "JournalIssue": {"Volume": "120", "Issue": "51", "PubDate": {"Year": "2023", "Month": "Dec", "Day": "19"}}, "Title": "Proceedings of the National Academy of Sciences of the United States of America", "ISOAbbreviation": "Proc Natl Acad Sci U S A"}, "ArticleTitle": "Nasal delivery of polymeric nanoDisc mobilizes a synergy of central and peripheral amyloid-\u03b2 clearance to treat Alzheimer's disease.", "Pagination": {"StartPage": "e2304213120", "MedlinePgn": "e2304213120"}, "Abstract": {"AbstractText": ["The disequilibrium of amyloid \u03b2-peptide (A\u03b2) between the central and peripheral pools has been claimed as an initiating event in Alzheimer's disease (AD). In this study, we employ discoidal high-density lipoproteins (HDL-Disc) mimicking A\u03b2 antibody for directional flux of A\u03b2 from central to peripheral catabolism, with desirable safety and translation potential. Structurally, HDL-Disc assembly (polyDisc) is prepared with aid of chitosan derivative polymerization. After intranasal administration and response to slightly acidic nasal microenvironment, polyDisc depolymerizes into carrier-free HDL-Disc with chitosan derivatives that adhere to the mucosal layer to reversibly open tight junctions, helping HDL-Disc penetrate the olfactory pathway into brain. Thereafter, HDL-Disc captures A\u03b2 into microglia for central clearance or ferries A\u03b2 out of the brain for liver-mediated compensatory catabolism. For synergy therapy, intranasal administration of polyDisc can effectively reduce intracerebral A\u03b2 burden by 97.3% and vascular A\u03b2 burden by 73.5%, ameliorate neurologic damage, and rescue memory deficits in APPswe/PS1dE9 transgenic AD mice with improved safety, especially vascular safety. Collectively, this design provides a proof of concept for developing A\u03b2 antibody mimics to mobilize a synergy of central and peripheral A\u03b2 clearance for AD treatment."]}, "AuthorList": [{"Identifier": ["0000-0002-4137-2703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Zhang", "ForeName": "Huaqing", "Initials": "H"}, {"Identifier": ["0009-0002-7700-8580"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Chen", "ForeName": "Yun", "Initials": "Y"}, {"Identifier": ["0009-0003-9593-0242"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Yu", "ForeName": "Miao", "Initials": "M"}, {"Identifier": ["0009-0004-1943-5829"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Xi", "ForeName": "Yilong", "Initials": "Y"}, {"Identifier": ["0009-0004-5659-1986"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Han", "ForeName": "Guochen", "Initials": "G"}, {"Identifier": ["0000-0003-4759-5323"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Jin", "ForeName": "Yi", "Initials": "Y"}, {"Identifier": ["0009-0004-2093-6604"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Wang", "ForeName": "Gang", "Initials": "G"}, {"Identifier": ["0009-0008-5129-1529"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Sun", "ForeName": "Xinzhu", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}], "LastName": "Zhou", "ForeName": "Jianping", "Initials": "J"}, {"Identifier": ["0000-0003-2894-7303"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}], "LastName": "Ding", "ForeName": "Yang", "Initials": "Y"}], "GrantList": [{"GrantID": "82372113", "Agency": "MOST | National Natural Science Foundation of China (NSFC)", "Country": ""}, {"GrantID": "82104097", "Agency": "MOST | National Natural Science Foundation of China (NSFC)", "Country": ""}, {"GrantID": "82373815", "Agency": "MOST | National Natural Science Foundation of China (NSFC)", "Country": ""}, {"GrantID": "82073795", "Agency": "MOST | National Natural Science Foundation of China (NSFC)", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Proc Natl Acad Sci U S A", "NlmUniqueID": "7505876", "ISSNLinking": "0027-8424"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amyloid beta-Peptides"}, {"RegistryNumber": "9012-76-4", "NameOfSubstance": "Chitosan"}, {"RegistryNumber": "0", "NameOfSubstance": "Amyloid beta-Protein Precursor"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["metabolism"], "DescriptorName": "Amyloid beta-Peptides"}, {"QualifierName": ["metabolism"], "DescriptorName": "Chitosan"}, {"QualifierName": ["metabolism"], "DescriptorName": "Amyloid beta-Protein Precursor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Brain"}, {"QualifierName": [], "DescriptorName": "Mice, Transgenic"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}], "CoiStatement": "Competing interests statement:The authors declare no competing interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Long J. M., Holtzman D. M., Alzheimer disease: An update on pathobiology and treatment strategies. Cell 179, 312\u2013339 (2019).", "ArticleIdList": ["PMC6778042", "31564456"]}, {"Citation": "Huang L.-K., Chao S.-P., Hu C.-J., Clinical trials of new drugs for Alzheimer disease. J. Biomed. Sci. 27, 18 (2020).", "ArticleIdList": ["PMC6943903", "31906949"]}, {"Citation": "DeTure M. A., Dickson D. W., The neuropathological diagnosis of Alzheimer\u2019s disease. Mol. Neurodegener. 14, 32 (2019).", "ArticleIdList": ["PMC6679484", "31375134"]}, {"Citation": "Cheng Y., Tian D.-Y., Wang Y.-J., Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: Pathophysiology and therapeutic perspectives. Transl. Neurodegener. 9, 16 (2020).", "ArticleIdList": ["PMC7204069", "32381118"]}, {"Citation": "Greenberg S. M., et al. , Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat. Rev. Neurol. 16, 30\u201342 (2020).", "ArticleIdList": ["PMC7268202", "31827267"]}, {"Citation": "Wani A., et al. , Alborixin clears amyloid-\u03b2 by inducing autophagy through PTEN-mediated inhibition of the AKT pathway. Autophagy 15, 1810\u20131828 (2019).", "ArticleIdList": ["PMC6735498", "30894052"]}, {"Citation": "Zuroff L., Daley D., Black K. L., Koronyo-Hamaoui M., Clearance of cerebral A\u03b2 in Alzheimer\u2019s disease: Reassessing the role of microglia and monocytes. Cell Mol. Life Sci. 74, 2167\u20132201 (2017).", "ArticleIdList": ["PMC5425508", "28197669"]}, {"Citation": "Carlson C., et al. , Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer\u2019s disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement. 7, 396\u2013401 (2011).", "ArticleIdList": ["21784350"]}, {"Citation": "Gilman S., et al. , Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553\u20131562 (2005).", "ArticleIdList": ["15883316"]}, {"Citation": "Tarasoff-Conway J. M., et al. , Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 11, 457\u2013470 (2015).", "ArticleIdList": ["PMC4694579", "26195256"]}, {"Citation": "Xi Y., et al. , Versatile nanomaterials for Alzheimer\u2019s disease: Pathogenesis inspired disease-modifying therapy. J. Control. Release 345, 38\u201361 (2022).", "ArticleIdList": ["35257810"]}, {"Citation": "Robert J., et al. , Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. Mol. Neurodegener. 15, 23 (2020).", "ArticleIdList": ["PMC7093966", "32213187"]}, {"Citation": "Albargothy N. J., et al. , Convective influx/glymphatic system: Tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways. Acta Neuropathol. 136, 139\u2013152 (2018).", "ArticleIdList": ["PMC6015107", "29754206"]}, {"Citation": "Gu X., et al. , Clearance of two organic nanoparticles from the brain via the paravascular pathway. J. Control. Release 322, 31\u201341 (2020).", "ArticleIdList": ["32165238"]}, {"Citation": "Easton R., et al. , A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J. Clin. Pharmacol. 54, 301\u2013310 (2014).", "ArticleIdList": ["24122814"]}, {"Citation": "Gille A., Easton R., D\u2019Andrea D., Wright S. D., Shear C. L., CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol. 34, 2106\u20132114 (2014).", "ArticleIdList": ["24969776"]}, {"Citation": "Sweeney M. D., Zhao Z., Montagne A., Nelson A. R., Zlokovic B. V., Blood-brain barrier: From physiology to disease and back. Physiol. Rev. 99, 21\u201378 (2019).", "ArticleIdList": ["PMC6335099", "30280653"]}, {"Citation": "Lochhead J. J., Thorne R. G., Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv Rev. 64, 614\u2013628 (2012).", "ArticleIdList": ["22119441"]}, {"Citation": "Anselmo A. C., Gokarn Y., Mitragotri S., Non-invasive delivery strategies for biologics. Nat. Rev. Drug Discov. 18, 19\u201340 (2019).", "ArticleIdList": ["30498202"]}, {"Citation": "Casettari L., Illum L., Chitosan in nasal delivery systems for therapeutic drugs. J. Control. Release 190, 189\u2013200 (2014).", "ArticleIdList": ["24818769"]}, {"Citation": "Diaz D. B., Yudin A. K., The versatility of boron in biological target engagement. Nat. Chem. 9, 731\u2013742 (2017).", "ArticleIdList": ["28754930"]}, {"Citation": "Lim C., Hwang D. S., Lee D. W., Intermolecular interactions of chitosan: Degree of acetylation and molecular weight. Carbohydr. Polym. 259, 117782 (2021).", "ArticleIdList": ["33674019"]}, {"Citation": "Hsu L.-W., et al. , Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan. Biomaterials 33, 6254\u20136263 (2012).", "ArticleIdList": ["22681978"]}, {"Citation": "Costa C. P., Moreira J. N., Sousa Lobo J. M., Silva A. C., Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of studies. Acta Pharm. Sin. B 11, 925\u2013940 (2021).", "ArticleIdList": ["PMC8105874", "33996407"]}, {"Citation": "Alexander J. F., et al. , Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits. Theranostics 11, 3109\u20133130 (2021).", "ArticleIdList": ["PMC7847685", "33537077"]}, {"Citation": "Luo Q., et al. , A self-destructive nanosweeper that captures and clears amyloid beta-peptides. Nat. Commun. 9, 1802 (2018).", "ArticleIdList": ["PMC5935695", "29728565"]}, {"Citation": "Button E. B., et al. , ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice. Alzheimers Res. Ther 11, 44 (2019).", "ArticleIdList": ["PMC6515644", "31084613"]}, {"Citation": "Panza F., Lozupone M., Logroscino G., Imbimbo B. P., A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73\u201388 (2019).", "ArticleIdList": ["30610216"]}, {"Citation": "Liu Y.-H., et al. , Clearance of amyloid-beta in Alzheimer\u2019s disease: Shifting the action site from center to periphery. Mol. Neurobiol. 51, 1\u20137 (2015).", "ArticleIdList": ["24733588"]}, {"Citation": "Park L., et al. , Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U.S.A. 110, 3089\u20133094 (2013).", "ArticleIdList": ["PMC3581946", "23382216"]}, {"Citation": "Veitch D. P., et al. , Understanding disease progression and improving Alzheimer\u2019s disease clinical trials: Recent highlights from the Alzheimer\u2019s Disease Neuroimaging Initiative. Alzheimers Dement. 15, 106\u2013152 (2019).", "ArticleIdList": ["30321505"]}, {"Citation": "Anonymous, 2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement (2020), 10.1002/alz.12068.", "ArticleIdList": ["10.1002/alz.12068"]}, {"Citation": "Selkoe D. J., Hardy J., The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol. Med. 8, 595\u2013608 (2016).", "ArticleIdList": ["PMC4888851", "27025652"]}, {"Citation": "van Dyck C. H., Anti-Amyloid-\u03b2 Monoclonal antibodies for Alzheimer\u2019s disease: Pitfalls and promise. Biol. Psychiatry 83, 311\u2013319 (2018).", "ArticleIdList": ["PMC5767539", "28967385"]}, {"Citation": "De Strooper B., Lessons from a failed \u03b3-secretase Alzheimer trial. Cell 159, 721\u2013726 (2014).", "ArticleIdList": ["25417150"]}, {"Citation": "Doody R. S., et al. , Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 311\u2013321 (2014).", "ArticleIdList": ["24450890"]}, {"Citation": "Salloway S., et al. , Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 322\u2013333 (2014).", "ArticleIdList": ["PMC4159618", "24450891"]}, {"Citation": "Viola K. L., Klein W. L., Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 129, 183\u2013206 (2015).", "ArticleIdList": ["PMC4390393", "25604547"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "12", "Day": "17", "Hour": "9", "Minute": "45"}, {"Year": "2023", "Month": "12", "Day": "12", "Hour": "18", "Minute": "42"}, {"Year": "2023", "Month": "12", "Day": "12", "Hour": "13", "Minute": "43"}, {"Year": "2024", "Month": "6", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38085773", "PMC10743360", "10.1073/pnas.2304213120"]}}], "PubmedBookArticle": []}